🤝 Yesterday, we were delighted to be joined by colleagues from Prostate Cancer UK, Queen's University Belfast 🎓 & The Patrick G Johnston Centre for Cancer Research to explore new prostate cancer research in our FASTMAN Centre of Excellence We're excited to explore further collaborations in genomics, clinical trials and radiotherapy research

#BoneHealth in advanced #ProstateCancer: Findings from the #STAMPEDE Trial and hospital episode statistics - Noel Clarke, MD The Christie NHS joins Alicia Morgans, MD, MPH Dana-Farber to discuss this critical issue, particularly in pts undergoing ADT > bit.ly/3V1TWsq

🔖 This ASCO Educational Book chapter led by Dr Lisa Gudenkauf & Struan Gray summarises the 🔑 points: ascopubs.org/doi/10.1200/ED…

🧵 Excited to share our latest paper in JAMA Oncology! Omar El-Taji led this meta-analysis to explore 🫀cardiovascular (CV) risks associated with 💊 androgen receptor signalling inhibitors (ARSI) in advanced prostate cancer (PCa). GU Cancer Research group Division of Cancer Sciences #CardioOncology

Second #Stampede presentation today silke gillessen on metformin in M1HSPC. Borderline OS gain, ?more in HV disease. Significant metabolic gains all pts MRC Clinical Trials Unit at UCL The ICR

Abstract submission is now open for BAUS #NWU25 meeting. 🔑 details: Meeting date: 30/31st January 2025. Abstract deadline: 1st December 2024 To submit, and for more information, go to BAUSNW.org.uk

Please do submit your hard work to the #MWU25 meeting which promises to be another cracker!

Meta-analysis evaluates #cardiovascular risks of AR inhibitors in #ProstateCancer. Omar El-Taji & Ashwin Sachdeva discuss with Alicia Morgans, MD, MPH highlighting the importance of CV screening and monitoring when initiating ARSI treatment. #WatchNow > bit.ly/475dCRQ JAMA Oncology

Northwest Urology 2025 Regional meeting. What a meeting! Thank you to our wonderful speakers and delegates and sponsors. None of it possible without the amazing committee who I cannot thank enough! #NWU25

Editorial Comment: Artificial Intelligence–Based Assessment of Preoperative Body Composition Is Associated With Early Complications After Radical Cystectomy read the full article here! 👉 bit.ly/4aFPgjh #AUA #Urology #AUAmembers #TheVoiceofUrology

What a weekend for our research group at #EAU25 in Madrid! 🇪🇸 Grateful for the opportunity to share our work across prostate and penile cancers — and proud of the recognition it received! A quick roundup of our team’s highlights 👇

Struan Gray kicked off with a prize-winning 🏆 poster on using CT scans from the #STAMPEDE abi & abi+enza trials to measure bone mineral density to help assess the impact of adding ARPIs to ADT amongst M0 prostate cancer patients

Omar El-Taji followed up with another prize-winning 🏆 poster reporting the use of CT-derived abdominal aortic calcification to predict non-cancer mortality within the #STAMPEDE abiraterone & docetaxel trials

🚨We’re hiring The Christie NHS! Great opportunity for a motivated clinician to join us as a Clinical Research Fellow in Urology! 🏥 Gain hands-on experience in tertiary surgical uro-oncology 🔬 Contribute to impactful research in prostate cancer ✍️ healthjobsuk.com/job/v7230918

Can patterns in post-radiotherapy PSA blood test results help better predict #ProstateCancer recurrence? Jane Shortall and Alan McWilliam at Division of Cancer Sciences and The Christie NHS share interesting new findings in Phiro Tweets. Grab a ☕ and read more: doi.org/10.1016/j.phro…

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol sciencedirect.com/science/articl… In the STAMPEDE phase 3 trial, researchers evaluated whether adding metformin to standard of care

Online: Metformin for patients with metastatic #prostatecancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol silke gillessen, Nick James also on @Prof-Nick-James.bsky.social, Ashwin Sachdeva, and colleagues thelancet.com/journals/lanon…